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Hydralazine hydrochloride has a half-life of 2 to 4 hours with an oral bioavailability of 26-50%. Since 
hydralazine has a demethylating effect on various suppressor genes, it can be used in various types of 
cancer to support chemotherapy. The purpose of this study was to optimize and evaluate floating tablets 
of hydralazine hydrochloride designed to prolong the gastric residence time and to provide controlled 
release of the drug for 14 h. The floating tablets of hydralazine hydrochloride were prepared by the wet 
granulation method. Semi-synthetic polymers of hydroxy propyl methyl cellulose (HPMC K100M) and 
ethyl cellulose were used as the release retarding agents. A 22 factorial design was applied to systematically 
optimize the drug release profile. The concentrations of HPMC K100M and ethyl cellulose were optimized 
to provide controlled release of hydralazine for 14h. Non-Fickian diffusion release transport was confirmed 
as the release mechanism for the optimized formulation and the predicted values agreed well with the 
experimental values. Drug excipient compatibility studies were investigated by FTIR, DSC and XRD. 
These data indicate that there were no chemical interactions between the drug and the polymer. In vivo 
X-ray imaging showed floating tablet performance in rabbits.
Uniterms: Hydralazine/floating tablets/evaluation. Hydralazine/floating tablets/optimization. 
Hydralazine/floating tablets/controlled release. In vivo X-ray/tablets performance. Cancer/treatment.
O cloridrato de hidralazina apresenta meia-vida de 2 a 4 horas, com biodisponibilidade oral de 26-50%. 
Uma vez que a hidralazina possui efeito desmetilante em vários genes supressores, ela pode ser utilizada 
para diversos tipos de câncer, em apoio à quimioterapia. O objetivo deste estudo foi o de avaliar e 
otimizar comprimidos flutuantes de cloridrato de hidralazina, planejados para prolongar o tempo de 
residência gástrica e proporcionar liberação controlada do fármaco por 14 h. Os comprimidos flutuantes 
de cloridrato de hidralazina foram preparados pelo método de granulação úmida. Polímeros semi-sintéticos 
de hidroxipropiletil celulose (HPMCK100M) e acetato de celulose foram utilizados como agente de 
retardamento de liberação. Aplicou-se planejamento fatorial 22 para otimizar sistematicamente o perfil de 
liberação do fármaco. As concentrações de HPMCK100M e de etilcelulose foram otimizadas para se obter 
liberação controlada de hidralazina durante 14 h. O transporte de liberação de difusão não-Fickiana foi 
confirmado como o mecanismo de liberação para a formulação otimizada e os valores previstos estiveram 
de acordo com os valores experimentais. Estudos de compatibilidade entre fármaco e excipiente foram 
realizados por FTIR, DSC e DRX. Estes dados indicaram que não havia interação química entre o fármaco 
e o polímero. Imagens de raios-X in vivo mostraram o desempenho dos comprimidos flutuantes em coelhos.
Unitermos: Hidralazina/comprimidos flutuantes/avaliação. Hidralazina/comprimidos flutuantes/
otimização. Hidralazina/comprimidos flutuantes/liberação controlada. Raios X in vivo/desempenho de 
comprimidos. Cancer/tratamento.
INTRODUCTION
Oral drug delivery systems represent an important 
area of controlled drug delivery, as such dosage forms 
have the major advantage of patient compliance (Dalavi 
et al., 2010). The overall performance of oral controlled 
release drug delivery systems is limited by several factors 
such as physiological variability, gastric retention time, 
variation in physiological pH and a narrow absorption 
window. Gastric retention is useful for those drugs which 
(i) act locally (Zhenping et al., 2001; Yuveraj, Singh et 
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al., 2007); (ii) have a narrow absorption window in the 
small intestinal region (Streobel et al., 2006); (iii) are 
unstable in the intestinal environment and (iv) have poor 
solubility in a high pH environment. Various dosage 
forms have been developed for gastric retention; these 
include floating tablets (Sathis et al., 2011) floating beads, 
pellets, floating granules and floating microspheres. 
Hydralazine is a directly acting smooth muscle relaxant 
used to treat hypertension by acting as a vasodilator. It is 
the first-line therapy for hypertension in pregnancy along 
with methyldopa.The drug is insoluble in water and has 
a half-life of 2 to 4hours with an oral bioavailability of 
26-50%. In the recent years, more attention has been 
directed towards hydralazine, since it has a demethylating 
effect on various suppressor genes. Therefore, it can be 
used in various types of cancer to support chemotherapy 
(Melike, Benek, 2012; Song et al., 2009).In the present 
study, an attempt was made to optimize (Singh et al., 
2009) the concentration of semi-synthetic polymers for 
the controlled release of hydralazine and to minimize 
its side effects by administration of a lower dose. As 
hydralazine can also be used as a support in cancer therapy, 
the controlled release formulation was prepared using 
various polymers. Sodium bicarbonate was used as a gas 
generating agent. Drug-excipient compatibility was studied 
by Fourier transform infrared spectroscopy (FT-IR), 
differential scanning calorimetry (DSC) and X-ray 
diffraction(XRD). An in vivo X-ray imaging study was 
performed to show floating tablet performance in rabbits.
MATERIAL AND METHODS
Hydralazine was donated by Hetero Drugs Ltd., 
Hyderabad, India. HPMC K100M and ethyl cellulose were 
obtained as gift samples from Matrix Labs, Hyderabad. 
Other ingredients used were of analytical grade.
Optimization of formulation
The optimization technique encompassed designing 
a set of experiments that could reliably measure the 
response variables, fitting a mathematical model to the 
data, conducting appropriate statistical tests to assure that 
the best possible model was chosen, and determining the 
values of the independent formulation variables to produce 
the optimum response (Gupta et al., 2008).
Experimental design
In the preliminary studies, eight formulations with 
different drug/polymer ratios were formulated based on 
a 22 factorial design (Madan et al., 2009). The design 
included two factors each evaluated at two levels. The 
proportion of the retardant materials HPMC K100M (X1) 
and ethyl cellulose (X2) were selected as the independent 
variables. Drug release at 1.5 (Y1),4 (Y2), 8 (Y3) and 14 
hours (Y4) was selected as the dependent variable in this 
study. The plan of the experiment is given in Table I.
Preparation of tablets
The formulations were prepared by the wet 
granulation method (Garget al., 2009) at random following 
a 22 factorial design. The various excipients used are listed 
in Table II. All the ingredients, expect magnesium stearate 
and talc, were thoroughly mixed and passed through a 
no.60 sieve. Granulation was performed with a solution of 
0.5% PVP K 30 in ethyl alcohol. The wet mass was passed 
through a no.40 sieve and dried at 50 oC for 10 min. The 
dried granules were lubricated with magnesium stearate 
and talc and compressed into tablets using a Cadmach 21 
station rotary tablet compression machine.
In vitro buoyancy studies
The tablets were placed in a 100 mL beaker 
containing 0.1N HCl at a temperature of 37± 0.5 oC. The 
time taken for the tablet to rise to the surface is called 
the floating lag time. The total period of time the dosage 
form remains on the surface of the media is called the total 
floating time.
Dissolution studies
In vitro dissolution study of hydralazine was 
performed using a USP Type I basket dissolution apparatus 
in 900 mL of 0.1NHCl at 37 oC(50 rpm) (Sameer,Singh 
et al., 2011). Samples were withdrawn, filtered, suitably 
diluted and assayed at 302 nm on a UV spectrophotometer. 
The samples were then replaced with fresh dissolution 
medium.
TABLE I - Plan of the experiments with coded levels of the 
variables
Sl. No. Variables X1 X2
1 X0 - 1 - 1
2 X1 (HPMC K100M) 1 - 1
3 X2 (Ethyl cellulose) -1 1
4 X1X2 (Interaction) 1 1
5 Midpoint
6 Midpoint
7 Midpoint
8 Midpoint
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TABLE III - Experimental plan and observed response values from randomized runs in a 22 factorial design for the development of 
floating tablets containing hydralazine hydrochloride
Std Run
Factor1 Factor 2 Response 1 Response 2 Response 3 Response 4
HPMC K100 (X1) EC (X2) Dissolution 1.5 h Dissolution 4 h Dissolution 8 h Dissolution 14 h
8 1 125 30 17 49 70 92
6 2 125 30 20 52 71 94
5 3 125 30 19 49 69 92
7 4 125 30 17 50 72 95
2 5 150 20 8 49 68 92
4 6 150 40 27 46 63 87
3 7 100 40 25 52 75 98
1 8 100 20 28 61 72 97
TABLE II - Formulation of floating tablets of hydralazine
Ingredients F1 F2 F3 F4 F5 F6 F7 F8
Hydralazine 50 50 50 50 50 50 50 50
HPMCK100M 100 150 100 150 125 125 125 125
Ethyl cellulose 20 20 40 40 30 30 30 30
NaHCO3 45 45 45 45 45 45 45 45
Mgstearate 6 6 6 6 6 6 6 6
Talc 6 6 6 6 6 6 6 6
Lactose 58 8 38 3 38 38 38 38
Total wt. 300 300 300 300 300 300 300 300
All values are in given in mg
Kinetic modeling of drug release
The dissolution profile of all the batches was fitted 
to zero order, first order, Higuchi, Korsemeyer and Peppas 
models to ascertain the kinetic modeling of drug release 
(Dave et al., 2004).
Drug-polymer compatibility
FT-IR analysis
FT-IR was carried out to assess the interaction 
between the drug and the tablet excipients. For this, 
sufficient amounts of the pure drug and powdered 
hydralazine tablets were scanned over a wavenumber range 
of 4000 to 650 cm-1 at a resolution of 4 cm-1 on a BRUKER 
Alpha FT-IR spectrometer (serial number:200218). The 
system was operated in transmission mode.
DSC analysis
Thermal analysis were carried out using a differential 
scanning calorimeter (Perkin Elmer DSC Pyris-1, Perkin 
Elmer Inc.).
XRD studies
Diffractograms of the drug, HPMC and floating 
tablets were obtained using a Philips PW 1830 X-ray 
diffractometer.
In vivo radio imaging study
The optimized floating tablets excluding the drug 
and containing barium sulfate (50 mg per tablet) were 
prepared and studied for in vivo X-ray imaging study to 
establish the product performance in rabbits
RESULTS AND DISCUSSION
The floating tablets containing hydralazine 
hydrochloride were prepared by the wet granulation 
method at random following a 22 factorial design. 
According to this trial proposal, eight experimental 
formulations of floating tablets containing hydralazine 
hydrochloride were prepared. An overview of the 
experimental plan and observed response values are 
presented in Table III. The Design-Expert 7.1.6 software 
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provided suitable model equations involving the individual 
main factors and interaction factors for each investigated 
response after fitting these data. These models were 
evaluated statistically by applying one-way ANOVA. All 
these models were found to be significant (p < 0.05).
The model equations in terms actual factors 
generated by the Design-Expert 7.1.6 software are given 
below:
Dissolution after 1.5 h= 115.00 – 0.84 X1 – 2.35 X2 + 
0.022 X1X2 [R2 = 0. 0.9181; p = 0.0388];
Dissolution after 4 h= 83.50 – 0.18 X1 – 0.30 X2  
[R2 = 0.8954; p = 0.0338];
Dissolution after 8 h= 61.00 + 0.08 X1 + 0.95 X2 - 0.008 
X1X2 [R2 = 0.9204; p = 0.0372]; and 
Dissolution after 14 h= 94.00 + 0.02 X1 + 0.65 X2 - 
0.006 X1X2 [R2 = 0.9420; p = 0.0231]
The main effects of factors X1 and X2 were larger 
compared to the effects of their interaction, i.e. X1X2. 
The curvature effect was insignificant and the steepest 
ascent method was chosen for optimization. X1 was the 
major factor; an increased polymer concentration reduced 
drug release, while ethyl cellulose had a negligible effect 
on drug release. Ethyl cellulose and HPMC K100M 
interaction was insignificant.
The limit for the estimated response for the 
preparation of optimized floating tablets of hydralazine 
hydrochloride was considered to be for1.5 h: NMT 25%; 
4 h: 50-60%; 8 h: 60-70; and 14 h: NLT 80%. The overlay 
plot indicating the region of optimal process variable 
settings is presented in Figure 1.
ANOVA study
The coefficients of X1 were found to be significant 
at p<0.05, confirming the significant effect on the selected 
responses. Increasing the concentration of HPMC K100M 
resulted in a decrease in the release of hydralazine. This 
was found to be close to unity, indicating good estimation 
of the coefficient. Similarly, Ri-squared was close to zero, 
which led to a good model. The values of Prob>F were 
less than 0.05, which indicated that the model terms were 
significant. In all cases, “Pred R-squared” values were in 
reasonable agreement with the “Adj R-squared” values. 
Adeq-Precision is a measure of the signal to noise ratio; a 
ratio > 4 is desirable. In this case, the Adeq-Precision values 
were 9.41, 9.29, 10.39 and 11.60 for 1.5 h, 4 h, 8 h and 14 h, 
respectively, which indicated an adequate signal. However, 
both the variables favored the preparation of controlled 
release floating tablets of hydralazine. The statistical 
approach for formulation (optimization) is a useful tool, 
particularly when simultaneously evaluating several 
variables. The observed responses were in close agreement 
with the predicted values of the optimized formulations, 
demonstrating the feasibility of the optimization procedure 
for developing floating tablets of hydralazine hydrochloride.
According to the overlay plot (Figure 1), the 
optimum concentrations are 130 mg for X1 and 30 mg 
for X2.
In vitro buoyancy
All floating tablets of hydralazine hydrochloride 
floated well over a long period of time (not less than 
FIGURE 1 - Overlay plot indicating the region of optimal process variable settings in the development of floating tablets of 
hydralazine hydrochloride.
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24 hours) with no minimum floating lag time (12 to 30 
seconds) (Table IV). These floating tablets contained 
sodium bicarbonate as an effervescent agent. An 
effervescent agent generally produces CO2, which reduces 
the density of the system and makes it float on an aqueous 
medium.
In vitro dissolution
In vitro hydralazine hydrochloride release from 
various hydralazine hydrochloride floating tablets in 
0.1 N HCl is presented in Figure 2. The drug release 
was found to be sustained over a prolonged period of 
time (14 h). In these floating tablets, HPMC K100M and 
ethylcellulose were used as release retardant materials. 
The greater viscosity due to HPMC K100M may promote 
the formation of a highly viscous gel upon contact with 
aqueous fluids. This would retard the drug release rate 
from these floating tablets. A comparison of the percentage 
TABLE IV - Evaluation of the physicochemical parameters of hydralazine hydrochloride
Formulation 
code
Weight (mg) 
n = 20
Hardness ± SD 
(kg/cm2) 
n=10
Drug 
content % ± SD 
(n=3)
Friability 
(%)
Thickness 
(mm)
Floating lag 
time
Floating 
duration (h) 
n=3
F1 300.54±1.28 5.63±0.42 98.25±3.01 0.13 3.45±0.05 16 sec 24±1.00
F2 300.05±1.12 5.85±0.65 102.03±2.4 0.12 2.97±0.02 12 sec 24±0.05
F3 300.15±1.10 6.91±0.34 99.70±3.51 0.14 3.71±0.09 20 sec 24±1.05
F4 299.59±1.29 6.58±0.49 100.81±0.7 0.13 3.51±0.10 16 sec 24±0.07
F5 300.00±0.92 6.11±0.36 97.23±0.25 0.16 3.13±0.03 18 sec 24±0.05
F6 299.91±1.33 6.45±0.53 99.17±0.42 0.12 3.15±0.07 30 sec 24±1.00
F7 299.61±1.47 6.63±0.54 101.47±2.8 0.13 3.45±0.11 25 sec 24±0.06
F8 299.35±1.37 6.63±0.43 100.01±3.0 0.15 3.35±0.08 20 sec 24±0.04
Optimized 
formulation
299.57±1.30 6.92±0.33 98.45±3.5 0.12 3.87±0.08 15 sec 24±0.08
TABLE V - Comparison of percentage ofdrug release between the 
experimented (E) and predicted (P) values for the most probable 
optimal formulation
Time interval Predicted value Experimental value
1.5h NMT 25% 24.05
4h 50-60% 53.49
8h 60-70% 67.17
14h NLT 80% 85.26
of drug release using the Experimented (E) and Predicted 
(P) values for the most probable optimal formulation are 
given in Table V.
Analysis of drug release data
The drug release kinetics was evaluated using the 
linear regression method (Table VI). The best fit with 
FIGURE 2 - In vitro hydralazine hydrochloride release from hydralazine hydrochloride floating tablets in 0.1 N HCl.
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the highest coefficients of determination (R2) was shown 
by both the Higuchi and first order models followed by 
zero order, which indicates that drug release followed the 
diffusion mechanism. The results of the in vitro release 
data were fitted to the Korsemeyer-Peppas equation to 
analyze the release pattern of the drug from the polymeric 
system. The values of “n” were in the range of 0.48-0.55, 
indicating that drug release followed Fickian diffusion.
Drug-polymer compatibility
FT-IR analysis
T h e  F T- I R  s p e c t r a  o f  p u r e  h y d r a l a z i n e 
hydrochloride, the optimized formulation, HPMC 
K100M and ethyl cellulose are presented in Figure 3. The 
characteristic peaks were at 3218.41 cm-1 (N-H stretching), 
3028.47 cm-1(aromatic C-H stretching), 2974 cm-1 
TABLE VI - Drug release kinetics of floating tablets of hydralazine hydrochloride
Formulation code Zero order R2
First order 
R2
Higuchi kinetics 
R2
Koresmeyer-Peppas equation
n R2
F1 0.881 0.971 0.981 0.494 0.986
F2 0.911 0.947 0.995 0.489 0.996
F3 0.846 0.972 0.954 0.550 0.948
F4 0.914 0.896 0.996 0.461 0.999
F5 0.899 0.924 0.990 0.513 0.982
F6 0.864 0.964 0.976 0.516 0.972
F7 0.907 0.904 0.992 0.536 0.983
F8 0.905 0.913 0.991 0.533 0.983
Optimized 
formulation
0.931 0.975 0.995 0.480 0.991
FIGURE 3 - FTIR spectra of a. Pure drug b. Optimized formulation C.HPMC K100M d.Ethyl cellulose.
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FIGURE 4 - DSC thermograms of the pure drug (a), the optimized formulation (b), HPMC K 100M (c) and ethyl cellulose (d).
(CH stretching due to methyl groups), 2904-1674 cm-1 
(aromatic C-H vibrations), 2804 cm-1(C-H stretching), 
2029-1870 cm-1(C=C stretching) and 1673-1467 cm-1(C-C 
stretching due to the aromatic ring). In the optimized 
formulation, the main bands of hydralazine were detected 
at a lower intensity due to the polymers. The characteristic 
peaks present in the FT-IR spectrum of both HPMC 
K100M and ethylcellulose also appeared in the spectra 
of floating tablets of hydralazine hydrochloride. These 
phenomena indicate that there was an absence of any 
chemical interaction between the drug and the excipients.
DSC analysis
D S C  t h e r m o g r a m s  o f  p u r e  h y d r a l a z i n e 
hydrochloride, the optimized formulation, HPMC K100M 
and ethyl cellulose are presented in Figure 4. The DSC of 
pure hydralazine hydrochloride showed an endothermic 
peak at 282.5 °C, indicating the melting point of drug. In 
the DSC of HPMC K100M, broad endotherm at 83.9 °C 
was observed, which may have been due to evaporation of 
absorbed water, as well as a broad endotherm at 352.8 °C 
indicated the absence of a sharp melting point. In ethyl 
cellulose, a broad endotherm at 332.8 °C indicated the 
absence of a sharp melting point. The characteristic peaks 
that appeared in pure hydralazine hydrochloride were 
present in the optimized formulation and were absent 
in the DSC thermograms of both HPMC K100M and 
ethylcellulose. These results indicate the absence of any 
chemical interactions between the drug and the excipients 
used in the formulation.
XRD analysis
The XRD pattern of pure hydralazine hydrochloride, 
the optimized formulation, HPMC K100M and ethyl 
cellulose are presented in Figure 5. The XRD pattern 
of hydralazine hydrochloride indicated crystalline 
characteristics, which was similar to the pattern of the 
optimized floating tablets of hydralazine hydrochloride; 
the polymer diffractograms showed an amorphous pattern.
In vivo radio imaging study
The optimized floating tablets excluding the drug 
and containing barium sulfate (50 mg per tablet) were 
prepared and studied in an in vivo X-ray imaging study to 
establish product performance in rabbits. An X-ray image 
is shown in Figure 6. X-ray images were taken at 0.5, 2 
and 6 h. The presence of the floating tablet in the upper 
gastrointestinal tract was clearly observed in these X-ray 
images. The in vivo X-ray imaging study clearly indicated 
that the prepared optimized floating tablet was retained 
in the rabbit stomach over a prolonged period of time 
and had good in vivo performance. Ethical clearance for 
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the handling of experimental animals was obtained from 
the Vishnu institutional animal ethical committee (IAEC 
No.1358/ac/10/cpcsea) constituted for this purpose.
CONCLUSION
A floating drug delivery system is a promising 
approach to achieve in vitro buoyancy and extended drug 
release using the synthetic polymer HPMCK100M, ethyl 
cellulose and gas generating agent sodium bicarbonate. A 
systematic study using a 22 factorial design revealed that, 
by selecting a suitable composition of HPMCK100M 
and ethyl cellulose, the desired dissolution profile could 
be achieved. The regression coefficient (R2) values of 
the release data of all the formulations were obtained by 
the curve fitting method for the zero order, first order, 
Higuchi and the Korsemeyer-Peppas models. Most of 
the formulations followed the Korsemeyer and Higuchi 
models. The R2 value of the optimized formulation 
was 0.991 and the n value was 0.48, indicating Fickian 
release governed by drug diffusion and the absence of an 
interaction between the drug and the polymer. An in vivo 
X-ray imaging study clearly indicated that the prepared 
optimized floating tablet was retained in the rabbit stomach 
over a prolonged period of time and showed good in vivo 
performance.
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